Price Alert

Dr. Reddy's Laboratories ... (RDY)

NYSE: RDY · Real-Time Price · USD

14.12

-0.14 (-0.98%)

At close: Aug 14, 2025, 3:59 PM

14.00

-0.85%

After-hours: Aug 14, 2025, 05:16 PM EDT

-0.98% (1D)

Bid	13.35
Market Cap	11.76B
Revenue (ttm)	334.26B
Net Income (ttm)	56.8B
EPS (ttm)	0.78
PE Ratio (ttm)	18.1
Forward PE	0.22
Analyst	Strong Buy

Ask	15.3
Volume	1,599,186
Avg. Volume (20D)	1,516,508
Open	14.26
Previous Close	14.26
Day's Range	14.06 - 14.30
52-Week Range	12.26 - 16.85
Beta	0.31

About RDY

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RDY

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RDY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Dr. Reddy's Laboratories Limited is scheduled to release its earnings on Nov 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+5.29%

Dr. Reddy's Laboratories shares are trading higher... Unlock content with Pro Subscription

3 months ago

+3.96%

Dr. Reddy's Laboratories shares are trading hgher on possible continued strength after reporting better-than-expected Q4 financial results on Friday.

News

3 weeks ago · zacks.com

Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

3 weeks ago · seekingalpha.com

Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasim...

3 weeks ago · businesswire.com

Dr. Reddy's Q1FY26 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.

3 weeks ago · reuters.com

India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wed...

4 weeks ago · zacks.com

New Strong Sell Stocks for July 18th

ACHC, CNL and RDY have been added to the Zacks Rank #5 (Strong Sell) List on July 18, 2025.

2 months ago · zacks.com

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

2 months ago · businesswire.com

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

3 months ago · seekingalpha.com

Dr. Reddy's Continues To Be A Good Buy At Current Valuation

I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY r...